Turmesac® is supported by a multidisciplinary preclinical research programme covering anti-inflammatory activity, antioxidant protection, liver-cell protection, bioavailability, safety and cytotoxic activity in selected cancer cell models.
Turmesac® is supported by 12 preclinical studies conducted across in-vitro and in-vivo models, together with six international publications. Key papers published between 2019 and 2020 are summarised in the study index below.
Explore cell-based and animal studies investigating the biological activity of Turmesac®. Research models include LPS-stimulated macrophages, hydrogen peroxide-stressed human liver cells, chemically induced inflammation, paracetamol-induced liver toxicity and human cancer cell lines.
Explore Preclinical Research →Research has evaluated Turmesac® for antioxidant activity, intracellular reactive oxygen species modulation, suppression of pro-inflammatory cytokines and cytotoxic activity in HeLa and MCF-7 cancer cell models. These findings are preclinical.
Explore the Benefits →Acute oral toxicity testing evaluated doses up to 2,000 mg/kg body weight, with no reported mortality or acute toxic symptoms. A 28-day sub-acute study evaluated daily doses of 250, 500 and 1,000 mg/kg, with no reported Turmesac®-related changes.
Review Safety and Toxicology →| Year | Study | Design | Experimental N | Principal finding | Journal |
|---|---|---|---|---|---|
| 2020 | Pharmacological evaluation of hepatoprotective activity of Turmesac® on paracetamol-induced liver toxicity in rats | In-vivo, paracetamol-induced hepatotoxicity, silymarin-controlled | 30 rats, 6 per group | Turmesac® at 250 and 500 mg/kg reduced SGOT, SGPT and bilirubin and increased GSH, SOD, catalase and total protein compared with toxic control | European Journal of Biomedical and Pharmaceutical Sciences |
| 2020 | In-vivo anti-inflammatory activity of Turmesac® on chemically induced inflammation | Croton oil ear-edema model in mice and histamine paw-edema model in rats | 30 mice and 30 rats | The 500 mg/kg dose produced 58.65% ear-edema inhibition at 2 hours and 57.25% at 4 hours, with significant paw-edema reduction | European Journal of Biomedical and Pharmaceutical Sciences |
| 2020 | Evaluation of the anticancer properties of Turmesac® in human cervical adenocarcinoma | HeLa cell MTT assay, apoptosis and cell-cycle analysis | n=3 laboratory replicates | IC₅₀ was 115.12 µg/mL; exposure increased apoptotic-cell populations and affected cell-cycle distribution | Asian Journal of Pharmaceutical and Clinical Research |
| 2020 | In-vitro anti-inflammatory and hepatoprotective activity of Turmesac® | HepG2 liver cells and RAW 264.7 macrophages, flow cytometry | n=3 laboratory replicates | At 50 µg/mL, Turmesac® reduced H₂O₂-associated ROS fluorescence and lowered LPS-induced IL-8 and IL-12 expression | International Journal of Pharmacy and Pharmaceutical Sciences |
| 2019 | Evaluation of hepatoprotective, antioxidant and cytotoxic properties of aqueous turmeric-rhizome extract | HUH-7 and MCF-7 cell assays plus DPPH antioxidant assay | Cell-line and laboratory assays | Dose-responsive protection in H₂O₂-stressed liver cells, DPPH antioxidant activity and an MCF-7 IC₅₀ of 163.19 µg/mL | Journal of Medicinal Plants Research |
The liver study reported dose-dependent biochemical and histological protection, with the 500 mg/kg group showing greater improvement than the 250 mg/kg group. The animal inflammation paper reported significant effects in two acute inflammation models. The cell-based studies provide mechanistic evidence involving ROS, IL-8, IL-12, apoptosis and cell-cycle distribution.
Publications, preclinical study summaries, safety information and technical documentation are available on request.
